451 related articles for article (PubMed ID: 25089529)
1. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
2. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.
Eldredge-Hindy H; Ohri N; Anne PR; Eschelman D; Gonsalves C; Intenzo C; Bar-Ad V; Dicker A; Doyle L; Li J; Sato T
Am J Clin Oncol; 2016 Apr; 39(2):189-95. PubMed ID: 24441583
[TBL] [Abstract][Full Text] [Related]
4. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
[TBL] [Abstract][Full Text] [Related]
6.
Kurilova I; Beets-Tan RGH; Ulaner GA; Boas FE; Petre EN; Yarmohammadi H; Ziv E; Deipolyi AR; Brody LA; Gonen M; Sofocleous CT
Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1419-1427. PubMed ID: 29766239
[TBL] [Abstract][Full Text] [Related]
7. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
[TBL] [Abstract][Full Text] [Related]
8. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
Kousik V; Promila P; Verma R; Gupta A
Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Radioembolization in Elderly (≥ 70 Years) and Younger Patients With Unresectable Liver-Dominant Colorectal Cancer.
Kennedy AS; Ball DS; Cohen SJ; Cohn M; Coldwell D; Drooz A; Ehrenwald E; Kanani S; Rose SC; Nutting CW; Moeslein FM; Savin MA; Schirm S; Putnam SG; Sharma NK; Wang EA;
Clin Colorectal Cancer; 2016 Jun; 15(2):141-151.e6. PubMed ID: 26541321
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of yttrium-90 radioembolization for unresectable liver metastases of melanoma.
Jia Z; Jiang G; Zhu C; Wang K; Li S; Qin X
Eur J Radiol; 2017 Jul; 92():111-115. PubMed ID: 28624008
[TBL] [Abstract][Full Text] [Related]
12. Complete eradication of hepatic metastasis from colorectal cancer by Yttrium-90 SIRT.
Garrean S; Muhs A; Bui JT; Blend MJ; Owens C; Helton WS; Espat NJ
World J Gastroenterol; 2007 Jun; 13(21):3016-9. PubMed ID: 17589957
[TBL] [Abstract][Full Text] [Related]
13. Single-institution experience with selective internal radiation therapy (SIRT) for the treatment of unresectable colorectal liver metastases.
O'Leary C; Greally M; McCaffrey J; Hughes P; Lawler LLP; O'Connell M; Geoghegan T; Farrelly C
Ir J Med Sci; 2019 Feb; 188(1):43-53. PubMed ID: 29511912
[TBL] [Abstract][Full Text] [Related]
14. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review.
Jia Z; Wang W
Eur J Radiol; 2018 Mar; 100():23-29. PubMed ID: 29496075
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.
Sofocleous CT; Garcia AR; Pandit-Taskar N; Do KG; Brody LA; Petre EN; Capanu M; Longing AP; Chou JF; Carrasquillo JA; Kemeny NE
Clin Colorectal Cancer; 2014 Mar; 13(1):27-36. PubMed ID: 24370352
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
17. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
18. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.
Michl M; Haug AR; Jakobs TF; Paprottka P; Hoffmann RT; Bartenstein P; Boeck S; Haas M; Laubender RP; Heinemann V
Oncology; 2014; 86(1):24-32. PubMed ID: 24401529
[TBL] [Abstract][Full Text] [Related]
19. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
[TBL] [Abstract][Full Text] [Related]
20. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]